<DOC>
	<DOCNO>NCT02624180</DOCNO>
	<brief_summary>The investigator study whether anti-inflammatory intervention improves impair coronary endothelial function ( CEF ) HIV+ people subclinical coronary artery disease ( CAD ) .</brief_summary>
	<brief_title>Inflammatory Pathogenesis Coronary Atherosclerosis HIV</brief_title>
	<detailed_description>Survival people HIV significantly improve use antiretroviral therapy ( ART ) HIV+ people experience increase burden chronic disease , include coronary atherosclerosis coronary artery disease ( CAD ) . HIV patient manifest increase risk CAD consequences possibly due interplay inflammation traditional risk factor ( smoking , high cholesterol , poor diet ) , latter accentuate ART . What investigator study program function coronary artery particular inner line artery call endothelium patient HIV . The endothelium several important function ; one condition stress release substance call nitric oxide increase size artery increase blood flow . When function normally artery increase much blood flow increase stress . The investigator study coronary artery function magnetic resonance imaging , MRI . MRI method obtain image happen inside body . MRI involve radiation , x-ray , injection contrast . The investigator measure flow artery dimension artery rest handgrip stress learn extent artery dilate flow increase stress . The investigator believe inflammation interfere normal function decrease inflammation abnormal endothelial function may improve . Colchicine anti-inflammatory agent approve Food Drug Administration ( FDA ) treat arthritis condition . This drug approve use suppress inflammation patient coronary artery disease improve coronary artery endothelial function . The FDA allow use colchicine placebo research study . This study involve 24 week colchicine placebo 3 Magnetic Resonance Imaging ( MRI ) scan heart study procedure .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Colchicine</mesh_term>
	<criteria>Patients either gender 21 year age old ( upper age limit ) , HIV positive take stable ART ( change ART regimen last 6 month ) , Computed tomography ( CT ) compute tomographic angiogram ( CTA ) demonstrate . ) coronary calcium score &gt; 10 Agatston unit ii . ) least one coronary artery &gt; 50 % luminal stenosis , Undetectable HIV viral load , Abnormal CEF baseline ( &lt; =7ml/min change CBF IHE compare rest value ) . Patients unable understand risk , benefit , alternative participation give meaningful consent , Patients contraindication MRI implant metallic object ( preexist cardiac pacemaker , cerebral clip ) indwell metallic projectile , History clinical CAD , include acute coronary syndrome , myocardial infarction revascularization , Resting ECG evidence Q wave myocardial infarction , Pregnant woman , Recent history cocaine heroin use , Moderate great renal impairment ( estimate glomerular filtration rate &lt; 45ml/min ) , Moderatesevere hepatic disease ( elevation hepatic transaminase &gt; 3x upper limit normal ) , Leukopenia ( &lt; 5000/mm3 ) thrombocytopenia ( &lt; 150,000/mm3 ) , CD4 &lt; 200 cell/mm3 , Chronic inflammatory condition lupus rheumatoid arthritis , ulcerative colitis Crohn 's disease , Requirement , intolerance , colchicine , Women childbearing potential ( even use oral contraceptive agent ) intention breastfeed , Chronic , continuous use oral IV steroid therapy immunosuppressive biologic response modifier antiinflammatory agent ( chronic nonsteroidal antiinflammatory drug ( NSAIDs ) acetylsalicylic acid ( ASA ) &gt; 81mg daily ) , History chronic pericardial effusion , pleural effusion , ascites peripheral neuropathy , Taking protease inhibitor , cobicistat cytochrome P450 isoform 3A4 ( CYP3A4 ) inhibitor .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>